Hormone Refractory Prostate Cancer (HRPCA) Market Report

USA Hormone Refractory Prostate Cancer (HRPCA) Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Oct 08, 2022
  • PAGES：172
  • REPORT CODE：GMM1264550
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.

    This report offers an overview of the market trends, drivers, and barriers with respect to the USA Hormone Refractory Prostate Cancer (HRPCA) market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Hormone Refractory Prostate Cancer (HRPCA) market. Detailed analysis of key players, along with key growth strategies adopted by Hormone Refractory Prostate Cancer (HRPCA) industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Astellas Inc

    • Dendreon Corporation, Bayer AG

    • Johnson & Johnson

    By Type:

    • Chemotherapy

    • Hormonal Therapy

    • Immunotherapy

    • Radiation Therapy

    • Surgery

    By End-User:

    • Hospitals

    • Ambulatory Surgical Centers

    • Specialty Clinics

    By Region:

    • West USA

    • South USA

    • Middle West USA

    • Northeast USA

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Hormone Refractory Prostate Cancer (HRPCA) Market

    • 1.3 Market Segment by Type

      • 1.3.1 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Chemotherapy from 2016 to 2027

      • 1.3.2 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Hormonal Therapy from 2016 to 2027

      • 1.3.3 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Immunotherapy from 2016 to 2027

      • 1.3.4 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Radiation Therapy from 2016 to 2027

      • 1.3.5 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Surgery from 2016 to 2027

    • 1.4 Market Segment by Application

      • 1.4.1 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Hospitals from 2016 to 2027

      • 1.4.2 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Ambulatory Surgical Centers from 2016 to 2027

      • 1.4.3 USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Hormone Refractory Prostate Cancer (HRPCA) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Hormone Refractory Prostate Cancer (HRPCA) by Major Types

      • 3.4.1 Market Size and Growth Rate of Chemotherapy

      • 3.4.2 Market Size and Growth Rate of Hormonal Therapy

      • 3.4.3 Market Size and Growth Rate of Immunotherapy

      • 3.4.4 Market Size and Growth Rate of Radiation Therapy

      • 3.4.5 Market Size and Growth Rate of Surgery

    4 Segmentation of Hormone Refractory Prostate Cancer (HRPCA) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Hormone Refractory Prostate Cancer (HRPCA) by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hormone Refractory Prostate Cancer (HRPCA) in Hospitals

      • 4.4.2 Market Size and Growth Rate of Hormone Refractory Prostate Cancer (HRPCA) in Ambulatory Surgical Centers

      • 4.4.3 Market Size and Growth Rate of Hormone Refractory Prostate Cancer (HRPCA) in Specialty Clinics

    5 Market Analysis by Regions

    • 5.1 USA Hormone Refractory Prostate Cancer (HRPCA) Production Analysis by Regions

    • 5.2 USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on USA Economy

    6 West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis

    • 6.1 West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major Types

    • 6.2 West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major End-Users

    7 South USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis

    • 7.1 South USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major Types

    • 7.2 South USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major End-Users

    8 Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis

    • 8.1 Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major Types

    • 8.2 Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major End-Users

    9 Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis

    • 9.1 Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major Types

    • 9.2 Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Landscape Analysis by Major End-Users

    10 Major Players Profiles

      • 10.1 Astellas Inc

        • 10.1.1 Astellas Inc Company Profile and Recent Development

        • 10.1.2 Market Performance

        • 10.1.3 Product and Service Introduction

      • 10.2 Dendreon Corporation, Bayer AG

        • 10.2.1 Dendreon Corporation, Bayer AG Company Profile and Recent Development

        • 10.2.2 Market Performance

        • 10.2.3 Product and Service Introduction

      • 10.3 Johnson & Johnson

        • 10.3.1 Johnson & Johnson Company Profile and Recent Development

        • 10.3.2 Market Performance

        • 10.3.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Chemotherapy from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Hormonal Therapy from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Immunotherapy from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Radiation Therapy from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Surgery from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2020

    • Figure Market Share by Type in 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Hospitals from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Ambulatory Surgical Centers from 2016 to 2027

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Market Size and Growth Rate of Specialty Clinics from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2020

    • Figure Market Share by End-User in 2027

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Hormone Refractory Prostate Cancer (HRPCA) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2019

    • Figure Market Share of TOP 5 Players in 2019

    • Figure Market Share of TOP 6 Players from 2016 to 2020

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Distribution Map of USA

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Hormone Refractory Prostate Cancer (HRPCA)

    • Figure Development Trends of Different Types

    • Table Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Hormone Refractory Prostate Cancer (HRPCA) by Different Types from 2016 to 2027

    • Table Consumption Share of Hormone Refractory Prostate Cancer (HRPCA) by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Chemotherapy

    • Figure Market Size and Growth Rate of Hormonal Therapy

    • Figure Market Size and Growth Rate of Immunotherapy

    • Figure Market Size and Growth Rate of Radiation Therapy

    • Figure Market Size and Growth Rate of Surgery

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Hormone Refractory Prostate Cancer (HRPCA) by Different End-Users from 2016 to 2027

    • Table Consumption Share of Hormone Refractory Prostate Cancer (HRPCA) by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospitals

    • Figure Market Size and Growth Rate of Ambulatory Surgical Centers

    • Figure Market Size and Growth Rate of Specialty Clinics

    • Table USA Hormone Refractory Prostate Cancer (HRPCA) Production by Regions

    • Table USA Hormone Refractory Prostate Cancer (HRPCA) Production Share by Regions

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Production Share by Regions in 2016

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Production Share by Regions in 2021

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Production Share by Regions in 2027

    • Table USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by Regions

    • Table USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Regions

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Regions in 2016

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Regions in 2021

    • Figure USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Regions in 2027

    • Table West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by Types from 2016 to 2027

    • Table West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types from 2016 to 2027

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2016

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2021

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2027

    • Table West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by End-Users from 2016 to 2027

    • Table West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users from 2016 to 2027

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2016

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2021

    • Figure West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2027

    • Table South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by Types from 2016 to 2027

    • Table South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types from 2016 to 2027

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2016

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2021

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2027

    • Table South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by End-Users from 2016 to 2027

    • Table South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users from 2016 to 2027

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2016

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2021

    • Figure South USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2027

    • Table Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by Types from 2016 to 2027

    • Table Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types from 2016 to 2027

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2016

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2021

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2027

    • Table Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by End-Users from 2016 to 2027

    • Table Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users from 2016 to 2027

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2016

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2021

    • Figure Middle West USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2027

    • Table Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by Types from 2016 to 2027

    • Table Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types from 2016 to 2027

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2016

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2021

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by Types in 2027

    • Table Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption by End-Users from 2016 to 2027

    • Table Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2016

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2021

    • Figure Northeast USA Hormone Refractory Prostate Cancer (HRPCA) Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Astellas Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Inc

    • Figure Sales and Growth Rate Analysis of Astellas Inc

    • Figure Revenue and Market Share Analysis of Astellas Inc

    • Table Product and Service Introduction of Astellas Inc

    • Table Company Profile and Development Status of Dendreon Corporation, Bayer AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dendreon Corporation, Bayer AG

    • Figure Sales and Growth Rate Analysis of Dendreon Corporation, Bayer AG

    • Figure Revenue and Market Share Analysis of Dendreon Corporation, Bayer AG

    • Table Product and Service Introduction of Dendreon Corporation, Bayer AG

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US